WALTHAM, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE) ("BeiGene"), a clinical-stage biopharmaceutical company developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that it will present updated data from the Phase I study of BGB-3111, its Bruton's tyrosine kinase (BTK) inhibitor, in patients with Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) and Waldenström's Macroglobulinemia (WM) at the 2016 American Society of Hematology (ASH) Annual Meeting. The ASH Annual Meeting will take place December 3-6, 2016 in San Diego, California. Oral Presentation, Abstract #642Title: Twice Daily Dosing with the Highly Specific BTK Inhibitor, BGB-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Authors: Constantine S. Tam, Stephen Opat, Gavin Cull, Judith Trotman, David Gottlieb, David Simpson, Paula Marlton, Mary Ann Anderson, Matthew Ku, David Ritchie, Sumita Ratnasingam, Bradley Augustson, Mark Kirschbaum, Lai Wang, Ling Xue, Jianxin Yang, Eric Hedrick, John F. Seymour, Andrew W. Roberts Presenter: Dr. Constantine Tam Session: 642. CLL: Therapy, excluding Transplantation: Targeted Therapy: Novel Agents and Combinations Date: Monday, December 5, 2016 Time: 8:15 AM PT Location: San Diego Convention Center, Room 5AB Oral Presentation, Abstract #1216 Title: High Major Response Rate, including Very Good Partial Responses (VGPR), in Patients (pts) with Waldenstrom Macroglobulinemia (WM) Treated with the Second Generation BTK Inhibitor BGB-3111: Expansion Phase Results from an Ongoing Phase I Study Authors: Constantine S. Tam, Judith Trotman, Stephen Opat, Paula Marlton, Gavin Cull, David Simpson, Matthew Ku, David Ritchie, Emma Verner, Sumita Ratnasingam, Mary Ann Anderson, Peter Wood, Mark Kirschbaum, Lai Wang, Ling Xue, Jianxin Yang, Eric Hedrick, John F. Seymour, Andrew W. Roberts Presenter: Dr. Constantine Tam Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma Clinical Studies: Novel Targeted Therapy in Low Grade NHL Date: Monday, December 5, 2016 Time: 7:00 PM PT Location: San Diego Convention Center, Ballroom 20BC About BGB-3111 BGB-3111 is a potent and highly selective investigational small molecule inhibitor of BTK. BGB-3111 has demonstrated higher selectivity against BTK than ibrutinib (the only BTK inhibitor currently approved by the U.S. Food and Drug Administration and the European Medicines Agency) based on biochemical assays, higher exposure than ibrutinib based on their respective Phase I experience, and sustained 24-hour BTK occupancy in both the blood and the lymph node.